Found: 20
Select item for more details and to access through your institution.
Obesity in late adolescence and incident type 1 diabetes in young adulthood.
- Published in:
- Diabetologia, 2022, v. 65, n. 9, p. 1473, doi. 10.1007/s00125-022-05722-5
- By:
- Publication type:
- Article
Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3058, doi. 10.1111/dom.15623
- By:
- Publication type:
- Article
Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 3054, doi. 10.1111/dom.15172
- By:
- Publication type:
- Article
Association of sodium‐glucose cotransporter‐2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD‐REAL 2 study.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1431, doi. 10.1111/dom.14356
- By:
- Publication type:
- Article
Acute renal outcomes with sodium‐glucose co‐transporter‐2 inhibitors: Real‐world data analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 2, p. 340, doi. 10.1111/dom.13532
- By:
- Publication type:
- Article
Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 1, p. 185, doi. 10.1007/s13300-019-00725-9
- By:
- Publication type:
- Article
A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 2, p. 683, doi. 10.1007/s13300-019-0583-9
- By:
- Publication type:
- Article
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01963-9
- By:
- Publication type:
- Article
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01829-0
- By:
- Publication type:
- Article
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01829-0
- By:
- Publication type:
- Article
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01829-0
- By:
- Publication type:
- Article
127-LB: Effectiveness and Safety of Empagliflozin in Routine Care in Europe and East Asia: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-127-LB
- By:
- Publication type:
- Article
1508-P: Trends in Treatment Initiation and Management of Type 2 Diabetes Mellitus: Analysis of 20 Years of Real-World Data.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1508-P
- By:
- Publication type:
- Article
Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults.
- Published in:
- Cardiovascular Diabetology, 2022, v. 21, n. 1, p. 1, doi. 10.1186/s12933-022-01521-9
- By:
- Publication type:
- Article
Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
- Published in:
- Cardiovascular Diabetology, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12933-021-01362-y
- By:
- Publication type:
- Article
Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study.
- Published in:
- Diabetes Therapy, 2017, v. 8, n. 5, p. 1047, doi. 10.1007/s13300-017-0297-9
- By:
- Publication type:
- Article
The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real‐world data in Israel.
- Published in:
- Endocrinology, Diabetes & Metabolism, 2020, v. 3, n. 3, p. 1, doi. 10.1002/edm2.124
- By:
- Publication type:
- Article
Real-World Use of Alirocumab: Experience from a Large Healthcare Provider.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 3, p. 1084, doi. 10.3390/jcm12031084
- By:
- Publication type:
- Article
Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting.
- Published in:
- Journal of Diabetes, 2018, v. 10, n. 1, p. 68, doi. 10.1111/1753-0407.12560
- By:
- Publication type:
- Article
Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel.
- Published in:
- Diabetes Care, 2022, v. 45, n. 12, p. 2926, doi. 10.2337/dc22-1253
- By:
- Publication type:
- Article